Exhibiting at VIV Asia 2025

Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC)

Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC) is a leading manufacturer and global supplier of veterinary vaccines, specializing in poultry, swine, canine, and feline vaccines. Founded in 1968 and headquartered in Daejeon, South Korea, CAVAC has built a reputation for high-efficacy immunization solutions that protect animal health and support sustainable livestock and pet care industries worldwide.

With over 50 years of expertise in vaccine development, CAVAC is a key player in preventative animal healthcare, leveraging advanced biotechnology, in-house R&D, and state-of-the-art GMP-certified production facilities to manufacture safe, effective, and globally compliant vaccines.

Core Business and Specialization

CAVAC specializes in research, development, production, and distribution of veterinary vaccines targeting highly contagious and economically significant diseases in livestock and companion animals. The company ensures high immunogenicity and safety profiles through precision-formulated inactivated, live, and recombinant vaccines.

Key Specializations:

• Poultry Vaccines – Comprehensive avian disease prevention programs.
• Swine Vaccines – Protection against porcine viruses and bacterial infections.
• Canine & Feline Vaccines – Broad-spectrum immunization for pet health and zoonotic disease control.

Product Portfolio

Poultry Vaccines

• Flu H9 ME+ND7 – Highly effective against avian influenza (H9N2) and Newcastle disease.
• Flu H9N2+ND – Dual protection against H9 avian influenza and Newcastle disease virus.
• ND-7 – Immunization against Newcastle disease for poultry farms.
• QX-IB, QX-Castle, IB-Castle – Targeted protection against infectious bronchitis virus (IBV).

Swine Vaccines

• SuiShot Circo One – Porcine circovirus (PCV) vaccine.
• SuiShot PT-100 – Prevention of Pasteurella multocida infection in swine.
• SuiShot AR-DT – Protects against atrophic rhinitis and swine pleuropneumonia.
• SuiShot APM-7 – Broad-spectrum protection against major respiratory pathogens.

Canine Vaccines

• CaniShot KC-Plus – Comprehensive kennel cough vaccine.
• CaniShot Cv – Canine coronavirus vaccine.
• CaniShot K5-Cv – Combined vaccine against distemper, hepatitis, parvovirus, parainfluenza, and coronavirus.
• CaniShot RV-K – Rabies virus vaccine.
• CaniShot DHPPL – 5-in-1 vaccine for core canine diseases.

Feline Vaccines

• FeliShot PHC – Triple protection against feline panleukopenia, herpesvirus, and calicivirus.

Research & Development

CAVAC invests over 12% of its annual revenue in R&D, focusing on novel vaccine technologies, enhanced antigen stability, and next-generation immunization platforms. The company operates multiple R&D centers, collaborating with veterinary research institutions and biotechnology firms to develop cutting-edge vaccines.

Key R&D Focus Areas

• Recombinant Vaccines – Advanced genetically engineered vaccines for livestock and pets.
• Antigen Purification Technologies – Higher immunogenicity and reduced side effects.
• Vaccine Delivery Innovations – Development of oral and intranasal vaccines.
• Disease Surveillance & Prevention – Real-time tracking of animal disease outbreaks.

Global Market Presence

CAVAC has a strong international footprint, exporting high-efficacy veterinary vaccines to over 40 countries, serving integrated poultry and swine farms, veterinary clinics, and pet care providers.

Key Export Markets

• Asia-Pacific: South Korea, China, Japan, Thailand, Vietnam, Indonesia.
• Europe: Germany, Netherlands, France, UK, Spain.
• North America: United States, Canada, Mexico.
• South America: Brazil, Argentina, Chile.
• Middle East & Africa: UAE, Egypt, South Africa.

Certifications & Compliance

CAVAC ensures strict regulatory compliance with global veterinary medicine safety and efficacy standards.

Industry Certifications

• ISO 9001:2015 – Quality Management System Certification.
• GMP Certified – Compliance with Good Manufacturing Practices for veterinary vaccines.
• OIE Standards – Adherence to World Organisation for Animal Health guidelines.
• HACCP Certified – Food safety and risk prevention for livestock production.
• EU-GMP Approval – Compliance with European veterinary pharmaceutical regulations.

Shipment and Export Capabilities

CAVAC leverages advanced cold-chain logistics and secure global distribution networks to ensure vaccine potency and efficacy throughout transit.

• Annual Vaccine Production Capacity: Over 500 million doses.
• Primary Shipping Ports: Incheon, Busan, Shanghai, Rotterdam.
• Distribution Channels: Direct partnerships with integrators, veterinary distributors, and national disease control agencies.

Customer Testimonials

CAVAC has earned trust and recognition from livestock producers, veterinarians, and pet health professionals worldwide.

"The Flu H9 ME+ND7 vaccine has provided outstanding protection against avian influenza and Newcastle disease, significantly improving flock health."
– Poultry Farm Operator, Thailand

"CaniShot KC-Plus has been a game-changer for our kennel operations, effectively preventing outbreaks of canine infectious respiratory disease."
– Veterinary Clinic Director, Germany

Major Achievements

• One of the Top 5 Veterinary Vaccine Manufacturers in South Korea.
• Over 500 million doses of veterinary vaccines produced annually.
• Expanded distribution network to over 40 countries worldwide.
• Continuous R&D investment exceeding 12% of company revenue.

Future Outlook

With growing global demand for high-efficacy animal vaccines, CAVAC remains at the forefront of veterinary biotechnology and preventive medicine, ensuring healthier livestock, safer food production, and improved pet care solutions worldwide.